Devices and TechnologyValidation of the single-cuff oscillometric blood pressure monitor InBody BPBIO320 for public use according to the 2010 European Society of Hypertension International ProtocolKollias, Anastasios; Stambolliu, Emelina; Kyriakoulis, Konstantinos G.; Papadatos, Stamatis S.; Stergiou, George S.Author Information Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece Correspondence to George S. Stergiou, MD, FRCP, Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, 152 Mesogion Avenue, Athens 11527, Greece Tel: +30 210 776 3117; fax: +30 210 771 9981; e-mail: email@example.com Received August 7, 2018 Received in revised form October 2, 2018 Accepted November 18, 2018 Blood Pressure Monitoring: February 2019 - Volume 24 - Issue 1 - p 30-32 doi: 10.1097/MBP.0000000000000359 Buy Metrics Abstract Objective The aim of this study was to assess the accuracy of the single-cuff oscillometric blood pressure (BP) monitor InBody BPBIO320 developed for self-measurement by adults in public spaces according to the 2010 European Society of Hypertension International Protocol (ESH-IP). Participants and methods Adults were recruited to fulfill the ESH-IP requirements. The same-arm sequential BP measurement method was used. Results A total of 38 participants were recruited and 33 were included in the analysis. The average difference between test and reference BP measurements was−0.4±5.3 (SD)/−0.5±4.6 mmHg (systolic/diastolic). The number of test–reference BP differences within 5, 10, and 15 mmHg was 73, 91, and 98 for systolic BP and 79, 93, and 99 for diastolic. The number of participants with at least two of their three BP differences within 5 mmHg was 28 for both systolic and diastolic BPs. The number of participants with none of their three BP differences within 5 mmHg was 1 for both systolic and diastolic BPs. Conclusion The InBody BPBIO320 device fulfilled the requirements of the ESH-IP validation protocol and can be recommended for clinical use in adults. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.